I have dabbled in and out the last two years. Watched it
I have dabbled in and out the last two years. Watched it sink down to under 5 cents over time since Feuerstein ripped the Eltoprazine Phase 2A Alzheimer's aggression results. I remember the day it hit 1 cent. Once I saw that, I accumulated a lot shares in the 2-3 cent range. Tried to get 1 cent shares but that never came back. Did get a lot in the 2.2-2.5 range. I believe the IP and pipe in general has possibly a few game changers, and almost no matter what the share count, the stock is worth 2-3 cents a share.
Excited to see where this goes. GO AMBS.
1
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
U.S. Latino leaders gathered for a historic delegation to Mexico, coinciding with the inauguration of Dra. Claudia Sheinbaum Pardo as Mexico's first female president back in 2024. This was no ordinary trip; it was a strategic move to tighten bonds between the two nations at a pivotal moment, hoping to reshape how Mexican-Americans influenced U.S. policy. Binational Ties:...
Continue Reading
The Future of Structural Heart Devices Market Growth The structural heart devices market is on an impressive growth trajectory, projected to reach approximately USD 25 billion within the coming years. This expansion is primarily driven by the escalating demand for innovative solutions to manage various structural heart conditions. Understanding Structural Heart Devices...
Continue Reading
Significant Changes at MediPharm Labs MediPharm Labs Corp. (TSX: LABS, OTCQX: MEDIF), a leader in pharmaceutical-quality cannabis extraction and hemp-based products, has announced the departure of its President and Co-Founder, Keith Strachan, from his management role. Effective immediately, Keith will transition to the Board of Directors, where his strategic input will...
Continue Reading
Interactive Brokers Group Reports Strong Financial Growth Interactive Brokers Group (NASDAQ: IBKR) has announced impressive financial results for the third quarter of 2024, capitalizing on a beneficent market following a U.S. interest rate cut. The company experienced significant year-over-year growth across key metrics such as client accounts, equity, and revenue....
Continue Reading
Overview of Recent Share Trading Activities Publicis Groupe has recently engaged in trading its own shares as part of a program approved during its Shareholders’ Meetings. This initiative underscores the company's commitment to managing its share capital effectively, reflecting its ongoing strategy to enhance shareholder value. Transaction Details During the designated...
Continue Reading
